2 28 June 2021 ADA R&D investor call Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), in which was filed with the SEC in February 2021 in continuation of the publication of the Annual Report behalf of Novo Nordisk, may contain forward- looking statements. Words such as ‘believe’, ‘expect’, ‘ma other words and terms of similar meaning in connection with any discussion of future operating or fin statements include, but are not limited to: • Statements of targets, plans, objectives or goals for future operations, including those related to product approvals as well as cooperation in relation thereto, • Statements containing projections of or targets for revenues, costs, income (or loss), earnings pe measures, • Statements regarding future economic performance, future actions and outcome of contingencie • Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward Nordisk cautions that a number of important factors, including those described in this presentation, co statements. Factors that may affect future results include, but are not limited to, global as well as local political and failure of projects related to research and/or development, unplanned loss of patents, interruptions o government-mandated or market- driven price decreases for Novo Nordisk’s products, introduction of market current and new products, exposure to product liability and legal proceedings and investigatio intellectual property protection and regulatory controls on testing, approval, manufacturing and mark divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to pandemics or other public health crises. For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or t risk factors in ‘Risk management’ of the Annual Report 2020. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revi new information, future events or otherwise. Important drug information • Victoza ® and Ozempic ® are approved for the management of type 2 diabetes only • Saxenda ® is approved in the USA and the EU for the treatment of obesity only and Wegovy TM is app
Download PDF file